IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Trial record 4 of 5 for:
"Acanthocheilonemiasis"
Epidemiology and Control of Mansonella Perstans Infection in Uganda
This study has been completed.
Sponsor:
DBL -Institute for Health Research and Development
Collaborator:
Ministry of Health, Uganda
Information provided by:
DBL -Institute for Health Research and Development
ClinicalTrials.gov Identifier:
NCT00215280
First received: September 21, 2005
Last updated: April 19, 2007
Last verified: April 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.
| Condition | Intervention |
|---|---|
| Mansonelliasis Pruritus Lymphoedema Abdominal Pains | Drug: ivermectin and albendazole |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda |
Resource links provided by NLM:
Genetics Home Reference related topics:
lymphedema-distichiasis syndrome
Genetic and Rare Diseases Information Center resources:
Acanthocheilonemiasis
Mansonelliasis
Lymphatic Filariasis
Helminthiasis
U.S. FDA Resources
Further study details as provided by DBL -Institute for Health Research and Development:
Primary Outcome Measures:
- microfilariae periodicity patterns
- epidemiology of M. perstans at community level
- clinical spectre among infected
- reduction in microfilaraemia
Secondary Outcome Measures:
- treatment effect on clinical manifestations
| Estimated Enrollment: | 1000 |
| Study Start Date: | November 2005 |
| Estimated Study Completion Date: | February 2006 |
Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M. perstans in Uganda with relevance to control
Specific objectives:
- To establish the pattern of diurnal periodicity of M. perstans microfilaraemia in humans
- To establish the patterns of M. perstans microfilaraemia and possible clinical manifestations related to this infection in two communities with medium to high endemicity
- To determine the efficacy of ivermectin alone and the combination of ivermectin and albendazole on M. perstans microfilaraemia.
Eligibility| Ages Eligible for Study: | 5 Years and older (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Individuals >= 5 years with or without M. perstans infection
Exclusion Criteria:
- Individuals < 5 years
- Pregnant women
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00215280
Please refer to this study by its ClinicalTrials.gov identifier: NCT00215280
Locations
| Uganda | |
| Luwero | |
| Luwero and Mukono, Luwero and Mukono Districts, Uganda | |
Sponsors and Collaborators
DBL -Institute for Health Research and Development
Ministry of Health, Uganda
Investigators
| Principal Investigator: | Asanta M Asio, Msc | Ministry of Health, Uganda |
More Information
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00215280 History of Changes |
| Other Study ID Numbers: |
MV917090205 |
| Study First Received: | September 21, 2005 |
| Last Updated: | April 19, 2007 |
Keywords provided by DBL -Institute for Health Research and Development:
|
Mansonella perstans microfilaraemia ivermectin albendazole Uganda |
Additional relevant MeSH terms:
|
Dipetalonema Infections Acanthocheilonemiasis Abdominal Pain Lymphedema Pruritus Mansonelliasis Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Signs and Symptoms, Digestive Lymphatic Diseases Skin Diseases Skin Manifestations Filariasis |
Spirurida Infections Secernentea Infections Nematode Infections Helminthiasis Parasitic Diseases Albendazole Ivermectin Anthelmintics Antiparasitic Agents Anti-Infective Agents Anticestodal Agents Antiplatyhelmintic Agents Antiprotozoal Agents Tubulin Modulators Antimitotic Agents |
ClinicalTrials.gov processed this record on July 11, 2017